Video

Thomas Krivak, MD, considers PARP inhibitors and their role in pathways and standardized care in the maintenance and recurrence settings.
Thomas Krivak, MD, describes the many considerations that pathway developers must weigh when designing ovarian cancer clinical pathways.
Bobby Daly, MD, MBA, details the enormous challenges of developing in-house clinical pathways.
Bobby Daly, MD, MBA, explains how clinical pathway developers can use ASCO’s Criteria for High-Quality Clinical Pathways to guide decision-making.
Listen to Winston Wong, PharmD, summarize the key sessions and topics on the agenda at the 2018 Clinical Pathways Congress this October in Boston, MA.
Journal of Clinical Pathways spoke with Andrew Hertler, MD, about the role of genomics influencing clinical pathways in the near future (September 8-10, 2017; Washington, DC).
Journal of Clinical Pathways spoke with Andrew York, PharmD, a CMS pharmacist, regarding the payer’s role—specifically, the Oncology Care Model’s role—in the transition towards value-based care (September 8-10, 2017; Washington, DC).
Journal of Clinical Pathways spoke with Robert Daly, MD, MBA, regarding the role of evidence in designing clinical pathways and the future of pathways in health care (September 8-10, 2017; Washington, DC).
Journal of Clinical Pathways spoke with James Mohler, MD, about the relationship between clinical pathways and the current treatment landscape for prostate cancer (September 8-10, 2017; Washington, DC).
Journal of Clinical Pathways spoke with Robin Zon, MD, FACP, FASCO​​​​​​​, about her role with the ASCO Task Force and her presentation at the Clinical Pathways Congress, "ASCO'S Policy on Clinical Pathways - Future Direction" (September 8-10, 2017; Washington, DC).